Ahead of World IVF Day, HRC Fertility Launches Innovative Clinical Trial with Gameto for More Approachable IVF
The clinical trial reflects HRC Fertility's ongoing mission to make fertility care more accessible while delivering high level treatment to patients. As a recognized leader in reproductive medicine, HRC Fertility remains dedicated to advancing innovative solutions that support improvement in outcomes and patient experience.
Unlike conventional IVF, which albeit modern in its approach, nonetheless can require two weeks of injections, Fertilo takes an alternative approach by aiming to mimic the natural environment of the ovary but in a lab setting. The goal is a potentially shorter protocol with just five days of oral medication, two injections, and an egg maturation within three days.
HRC Fertility is currently pre screening participants for the GAM-01 Study to further research this clinical trial protocol and outcomes. The trial will be led by Dr. Robert Boostanfar of HRC Fertility's Valley region, and includes physicians from HRC Fertility's Beverly Hills and Encino locations including Dr. Shahin Ghadir, Dr. Sasha Hakman, Dr. Rachel Mandelbaum, Dr. Alison Peck, Dr. David Tourgeman, Dr. Sahar Wertheimer, and Dr. Irene Woo. HRC Fertility is one of only a few IVF clinics in the United States to collaborate on this study, and thus far, the only IVF and fertility provider in Los Angeles offering this pioneering program.
"At HRC Fertility, we are proud to be at the forefront of advancing reproductive medicine," shares Dr. Robert Boostanfar, Board-certified Reproductive Endocrinologist of HRC Fertility and Principal Investigator of the study. "The Fertilo process has the potential to help make IVF more accessible to those who may have been discouraged by physical, emotional, or financial demands," adding "We are extremely excited to partner with Gameto on this study and look forward to assessing the potential alternative approach further."
Participants will undergo an abbreviated ovarian stimulation cycle followed by egg retrieval, after which immature eggs will be matured in the lab using the Fertilo process. The resulting embryos can be frozen on day five of development, with an embryo transfer to the patient scheduled within approximately two months.
Generally, participant criteria includes:
Participants be age 18-35Undergoing assisted reproductive treatmentBody Mass Index (BMI) 21-40Normal Uterine CavityAnti-Mullerian Hormone (AMH) > 3 ng/mLNo endometriosis or presence of endometriomaMale partner with adequate semen analysis
As with many studies, costs related to medication, egg retrieval, anesthesia, and frozen embryo transfer will typically be covered by the study sponsor but non-study related costs may not be covered, and study participant guidelines, parameters and restrictions apply.
About HRC Fertility
HRC Fertility is one of the most established providers of advanced IVF and fertility care, with locations across California including Los Angeles, Orange, San Bernardino, San Diego, and the Bay Area, with a Las Vegas location coming soon. For over 35 years, HRC Fertility has remained dedicated to helping hopeful parents preserve their family building options for the future or build families now through world-class assisted reproductive technology, compassion and innovation. For detailed information about HRC Fertility's services, locations, and providers, please visit www.havingbabies.com.
About Dr. Robert Boostanfar
Dr. Robert Boostanfar, MD, FACOG is a Board-Certified Reproductive Endocrinologist at HRC Fertility's Valley region seeing patients at the Valley region's Encino and Westlake Village locations. Dr. Robert Boostanfar is a leading researcher, and earned his undergraduate degree from the University of California, Los Angeles (UCLA) and graduated medical school from the University of Southern California. He completed his residency in Obstetrics and Gynecology in 1999 and his fellowship in the Division of Reproductive Endocrinology and Infertility in 2002 at the USC Los Angeles County Women's and Children's Hospital. Dr. Boostanfar has supported patients across spectrums and has been seen on Good Morning America, CNN, TLC, KTLA, CBS People Magazine and Vogue, in addition to a myriad of nominations and awards.
About Gameto
Gameto is a biotechnology company redefining women's healthcare through cellular engineering. Focused on solving major challenges in reproductive health, Gameto develops therapies that aim to modernize fertility care, ovarian aging, and menopause. Its lead technology, Fertilo, uses lab-grown ovarian support cells to reduce the physical, emotional, and financial strain of traditional IVF and egg freezing. Gameto's mission is to bring safer, faster, and more accessible fertility solutions to women everywhere.
Contact:
Elainie AndreopoulosIllumination PRElainie@illuminationpr.com
SOURCE: HRC Fertility
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Miami Herald
6 hours ago
- Miami Herald
General Atomics Electromagnetic Systems Highlights Its Missile Defense Portfolio at the 2025 Space and Missile Defense Symposium
HUNTSVILLE, AL / ACCESS Newswire / August 4, 2025 / General Atomics Electromagnetic Systems (GA-EMS) returns to the Space and Missile Defense Symposium to highlight its missile defense solutions supporting Golden Dome, a layered missile defense architecture designed to protect the nation from a range of advanced missile threats including hypersonic, ballistic and cruise missiles, as well as other airborne threats. GA-EMS will showcase the designs for their Bullseye™ missile and Long-Range Maneuvering Projectile (LRMP), with a 1:1 scale model and 1:2 scale model in their booth. The company has accelerated integration and testing of its missile defense technologies to demonstrate advanced capabilities and move rapidly toward field deployment. "Our LRMP aligns with dynamic defense requirements for improved long-range precision strikes and minimizes operational uncertainty by integrating into existing artillery systems," said Scott Forney, president of GA-EMS. "The next phase of full-system testing will validate the projectile's performance across complex scenarios and ensure seamless integration with missile defense frameworks." Bullseye is a Technology Readiness Level (TRL) 8 missile system that shares 80% of its components with combat-proven TRL 9 missile systems, fully validated through successful real-world operations. Attendees visiting Booth #531 will engage directly with GA-EMS experts to explore system designs and planned field-testing initiatives for both LRMP and Bullseye. GA-EMS will also feature its portfolio of laser weapon systems, hypersonics and sensor payloads for missile defense and tracking-offering greater flexibility and capability to support both offensive and defensive missions. About General Atomics Electromagnetic Systems General Atomics Electromagnetic Systems (GA-EMS) develops innovative technologies to create breakthrough solutions supporting operational environments from undersea to space. From electromagnetic, power generation and energy storage systems and space systems and satellites, to hypersonic, missile defense, and laser weapon systems, GA-EMS offers an expanding portfolio of capabilities for defense, government, and national security customers. GA-EMS also provides commercial products and services targeting hazardous waste remediation, oil and gas, and nuclear energy industries. For further information, visit Contact Information General Atomics Electromagnetic Systems Media Relations Media Relationsems-mediarelations@ SOURCE: General Atomics Electromagnetic Systems press release
Miami Herald
7 hours ago
- Miami Herald
Traveler Care Launches Global Medical Dispatch Platform to Help Travel Insurance Companies Cut ER Claims by 80%
NEW YORK CITY, NY / ACCESS Newswire / August 4, 2025 / Traveler Care, a breakthrough medical dispatch platform that brings urgent care directly to travelers in hotels, Airbnbs, and vacation rentals, has officially launched worldwide - offering travel insurance companies a high-impact solution to reduce avoidable emergency room and hospital claims. A Concierge Alternative to the Emergency Room Traveler Care connects travel insurers and their policyholders to a network of licensed, on-call providers who visit travelers in their accommodations - typically within 60-90 minutes. Conditions such as flu, food poisoning, dehydration, allergic reactions, UTIs, sprains, and wound care are treated on-site, eliminating the need for an ER visit. "In most cases, travelers just need a doctor - not a hospital admission," said Eli Ofel, founder of Traveler Care. "We've built a scalable, insurer-ready solution that saves money and delivers a far better traveler experience." Reduce Claims by $10,000+ Per Visit On average, a non-emergency ER visit costs travel insurers $13,000 to $17,000. Traveler Care treats the same conditions in-room for $1,700 to $3,000 - including diagnostics like mobile X-ray, ultrasound, IV therapy, and wound treatment. Pilot results have shown:- 83% reduction in ER claim volume- $10,000+ savings per case avoided- Higher satisfaction scores among travelers Built for Travel Insurance Partners Traveler Care is fully designed for insurance integration - with white-label and API options available for TPAs, underwriters, and global assistance networks. Platform features:- Nationwide U.S. coverage (with international expansion underway)- A robust dispatch network, for example companies like Leaa Health, Sickday, Heal, DocGo and more, any location that the travel insurance is experiencing high volume travel care will create a solution for that particular location within 60 days.- HIPAA-compliant documentation + one-click claims integration- Supports care delivery to hotels, Airbnbs, resorts, and serviced apartments Now Onboarding Insurance Companies Worldwide "We believe travel insurance companies shouldn't just pay for care - they should deliver it smarter," said Ofel. "With Traveler Care, you lower claims without compromising care." Insurance providers, TPAs, and global assistance companies are invited to partner and deploy in-room urgent care as part of their medical benefit stack. Contact To schedule a private demo or receive our ROI case study:Visit partners@ +1 (347) 733-0563 About Eli Ofel Eli Ofel is a serial entrepreneur and visionary behind multiple AI- and tech-powered platforms in healthcare, finance, and transportation. He is the founder and CEO of Traveler Care, Leaa Health, and With over 20 years of experience in healthcare operations, insurance workflows, and mobile logistics, Ofel brings a proven ability to bridge patient needs with scalable platform solutions - saving time, money, and lives. SOURCE: Traveler care press release
Yahoo
5 days ago
- Yahoo
Former nurse loses legal challenge over registration of private gender clinic
A former nurse has lost a High Court legal challenge over the health watchdog's decision to register England's first private clinic offering gender treatment to young people. Susan Evans and a mother known as XX took legal action against the Care Quality Commission (CQC) over its decision to register the Gender Plus Hormone Clinic (GPHC) in Birmingham in January last year. The two also challenged the regulator's decision last December to continue the clinic's registration and to allow it to prescribe cross-sex hormone treatment to 16 and 17-year-olds without conditions. The clinic, which was rated outstanding by the watchdog last year, treats people aged 16 and older, including through prescribing gender-affirming – masculinising or feminising – hormones, but, in line with the NHS, does not prescribe puberty blockers. Lawyers for the women told a hearing in June that the CQC had acted 'irrationally' and made decisions that were 'simply not open to it', given the NHS's stance on hormone treatment for children aged 16 and 17 in light of the Cass Review. The CQC and GPHC opposed the challenge, with barristers telling the hearing in London that the legal challenge was 'fatally flawed' and the clinic was found to be 'committed to the safety and best interests of its patients'. In a ruling on Thursday, Mrs Justice Eady dismissed the claim, saying there was 'no irrationality in the decisions reached' and they were within the 'rational range' of options available to the watchdog. Hormone treatment was previously provided on the NHS at the now-closed Gender Identity Development Service (Gids) run by Tavistock and Portman NHS Foundation Trust, where Ms Evans worked. But a review published by Baroness Cass in April last year said 'extreme caution' should be demonstrated when deciding to prescribe the treatment to 16 and 17-year-olds, and that there should be 'clear clinical rationale for providing hormones at this stage rather than waiting until an individual reaches 18'. The NHS has opened three specialist children's gender clinics and has plans for a further five covering the seven NHS regions in England by the end of 2026, but has said that all recommendations for hormone interventions must be endorsed by a national multi-disciplinary team (MDT). It is understood that the MDT has not yet received any recommendations for hormone treatment for 16 and 17-year-olds since the Cass Review. GPHC was set up by Dr Aidan Kelly and is led by nurse consultant Paul Carruthers, who both worked at Gids, and has previously said it primarily treats patients aged between 16 and 25, using its own MDT. Tom Cross KC, for Ms Evans and XX, said in written submissions that there were 'a number of key differences' between GPHC and NHS safeguards, including that referrals to the former came from Dr Kelly's company, Kelly Psychology, which is unregulated. He said in court that the CQC had 'not factored in' parts of the treatment process on the NHS, which 'serve as important safeguards' and were 'obviously material'. He said consideration of these points would have led to the treatment of under-18s being halted. Jamie Burton KC, for the CQC, said that there was 'ample evidence' that Kelly Psychology 'did not pose an unacceptable risk' to patients, and that a 'significant number' of those assessed by the company were not referred for treatment at GPHC. The court was told that the CQC found no evidence of 'improper decision making or anything that might flag a concern', and that the CQC 'had regard' to NHS processes. Peter Mant KC, for Gender Plus Healthcare Limited, said that there was no legal requirement for a private provider to mirror NHS care and that the clinic's model was 'entirely consistent' with the Cass Review and NHS policy. In a 64-page ruling, Mrs Justice Eady said: 'Accepting that (GPHC) could neither access the NHS national MDT nor precisely replicate it, but keeping in mind the purpose of the NHS model, I cannot say that the CQC's finding of sufficient alignment was outside the reasonable range of conclusions open to it.' She continued: 'The range was set by reference to the substance that underpinned the NHS structures, not merely the choices made as to the form that those structures should take. 'Applying that approach, as I am satisfied the CQC did, the decisions reached fall within the rational range, and the CQC was entitled to conclude that no further conditions were required.'
